Finance

Lists
CTNM:NASDAQ
Contineum Therapeutics Inc
US$ १०.७७
+१.९९%
(+०.२१) 1D
US$ १०.९५
+१.६७% (+०.१८)
After hours
Closed: नोभेम्बर ११, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
US$ १०.६८
High
US$ १०.९०
Low
US$ १०.५७
Mkt. cap
४२.२९ करोड
Avg. vol.
११.१० लाख
Volume
०.००
52-wk high
US$ १७.७८
52-wk low
US$ ६.७२
EPS
-US$ १.७७
Shares outstanding
३.५४ करोड
No. of employees
५१
Open
US$ १०.६८
High
US$ १०.९०
Low
US$ १०.५७
Mkt. cap
४२.२९ करोड
Avg. vol.
११.१० लाख
Volume
०.००
52-wk high
US$ १७.७८
52-wk low
US$ ६.७२
EPS
-US$ १.७७
Shares outstanding
३.५४ करोड
No. of employees
५१
News stories
From web sources and news partners
Investing.com
Investing.com
·
२ दिन पहिले
Contineum adds Qureight imaging tool to IPF drug trial
About Contineum Therapeutics Inc
CEO-
Employees५१
Founded२००९
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current US$ १०.७७
US$ ३०.०० (+१७८.५५%)
Average
US$ २२.१४ (+१०५.५७%)
Lowest
US$ १४.०० (+२९.९९%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Buy
Maintained
US$ २१.००
+९५%
11/03/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
US$ ३०.००
+१७८.६%
11/03/2026
Charles Moore
Robert W. Baird
Hold
Downgraded
US$ १४.००
+३०%
10/14/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
US$ १७.००
+५७.८%
10/12/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
US$ २८.००
+१६०%
10/12/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/30/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
US$ २३.००
+११३.६%
09/29/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
US$ २२.००
+१०४.३%
09/16/2026
Last report
२०२६ नोभेम्बर ३
Fiscal period
Q3 2026
-US$ ०.४९ / -US$ ०.४५
-८.२०%miss
Revenue / Est. (USD)
- / ०.००
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१.२० करोड
१.११ करोड
१.२० करोड
१.५३ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५१.१८ लाख
५७.६१ लाख
५४.५४ लाख
५७.०४ लाख
Operating expense
१.७१ करोड
१.६९ करोड
१.७४ करोड
२.१० करोड
Total operating expenses
१.७१ करोड
१.६९ करोड
१.७४ करोड
२.१० करोड
Operating income
-१.७१ करोड
-१.६९ करोड
-१.७४ करोड
-२.१० करोड
Other non operating income
-५१.०० हजार
-५७.०० हजार
-६८.०० हजार
-९३.०० हजार
EBT including unusual items
-१.५२ करोड
-१.४५ करोड
-१.५२ करोड
-१.८७ करोड
EBT excluding unusual items
-१.५२ करोड
-१.४५ करोड
-१.५२ करोड
-१.८७ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.५२ करोड
-१.४५ करोड
-१.५२ करोड
-१.८७ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.४९
-०.३९
-०.४०
-०.४९
Interest and investment income
२०.१० लाख
२५.०५ लाख
२३.४२ लाख
२३.६२ लाख
Interest expense
-
-
-
-
Net interest expenses
२०.१० लाख
२५.०५ लाख
२३.४२ लाख
२३.६२ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.७० करोड
-१.६८ करोड
-१.७३ करोड
-२.०९ करोड
Gain or loss from assets sale
-
२.०० हजार
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू